Table 1.
Clinical characteristics and outcomes of 20 AML1-ETO(+) AML patients.
| Median (range) | N (%) | PFS (%) | OS (%) | |
|---|---|---|---|---|
| Age (years) | 9 (2–15) | P = 0.215 | P = 0.656 | |
| >10 | 11 (55) | 71.6±14.0 | 81.8±11.6 | |
| <10 | 9 (45) | 44.4±16.6 | 76.2±14.8 | |
| Sex | P = 0.572 | P = 0.486 | ||
| Male | 11 (55) | 55.6±16.6 | 88.9±10.5 | |
| Female | 9 (45) | 61.4±15.3 | 72.7±13.4 | |
| WBC count ( × 109/L) | 33.6 (1.8-186.8) | P = 0.024 | P = 0.198 | |
| >14.1 | 10 (50) | 37.5±16.1 | 67.5±15.5 | |
| <14.1 | 10 (50) | 80.0±12.6 | 90.0±9.5 | |
| Gene mutation | P = 0.081 | P = 0.194 | ||
| KIT mutation | 6 (30) | 33.3±19.2 | 100.0±0.0 | |
| Without KIT mutation | 14 (70) | 70.1±12.6 | 71.4±12.1 | |
| ddPCR-Dx (copies/μl) | 88.4 (43.3-146.0) | P = 0.013 | P = 0.054 | |
| >92.5 | 7 (35) | 21.4±17.8 | 57.1±18.7 | |
| <92.5 | 13 (65) | 76.9±11.7 | 91.7±8.0 | |
| ddPCR-MRD1 (copies/μl) | 1.1 (0.08-5.5) | P = 0.116 | P = 0.061 | |
| >0.43 | 11 (55) | 42.4±15.6 | 63.6±14.5 | |
| <0.43 | 9 (45) | 77.8±13.9 | 100.0±0.0 | |
| Log reduction1 | P = 0.116 | P = 0.061 | ||
| >2.4 | 9(45) | 77.8±13.9 | 100.0±0.0 | |
| <2.4 | 11(55) | 42.4±15.6 | 63.6±14.5 | |
| ddPCR-MRD2 (copies/μl) | 1.9 (0.0-5.5) | P = 0.009 | P = 0.003 | |
| >0.75 | 7(35) | 21.4±17.8 | 42.9±18.7 | |
| <0.75 | 13(65) | 76.9±11.7 | 100.0±0.0 | |
| Log reduction2 | P = 0.045 | P = 0.008 | ||
| >2.2 | 12(60) | 75.0±12.5 | 100.0±0.0 | |
| <2.2 | 8(40) | 33.3±18.0 | 50.0±17.7 | |
| ddPCR-MRD3 (coies/μl) | 1.3 (0.0-8.6) | P = 0.013 | P = 0.146 | |
| >0.21 | 12(63) | 38.1±14.7 | 72.7±13.4 | |
| <0.21 | 7(37) | 100.00±0.00 | 100.0±0.0 | |
| Log reduction3 | P < 0.001 | P = 0.007 | ||
| >1.9 | 15(79) | 79.0±10.8 | 93.3±6.4 | |
| <1.9 | 4(21) | 0.00±0.00 | 33.3±27.2 |